UA89759C2 - Специфический связующий элемент, радиоактивно меченный 131и, который связывает человеческий ed-в фибронектина - Google Patents

Специфический связующий элемент, радиоактивно меченный 131и, который связывает человеческий ed-в фибронектина

Info

Publication number
UA89759C2
UA89759C2 UAA200603803A UAA200603803A UA89759C2 UA 89759 C2 UA89759 C2 UA 89759C2 UA A200603803 A UAA200603803 A UA A200603803A UA A200603803 A UAA200603803 A UA A200603803A UA 89759 C2 UA89759 C2 UA 89759C2
Authority
UA
Ukraine
Prior art keywords
binding member
specific binding
binds human
human fibronectin
radiolabelled
Prior art date
Application number
UAA200603803A
Other languages
English (en)
Ukrainian (uk)
Inventor
Лаура Борси
Барбара Карнемолла
Энрика Бальца
Патрициа Кастеллани
Лучано Царди
Маттиас Фрибе
Кристоф-Штефан Хильгер
Original Assignee
Филоджен С. П. А.
Байер Шеринг Фарма Акциенгезелльшафт
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Филоджен С. П. А., Байер Шеринг Фарма Акциенгезелльшафт filed Critical Филоджен С. П. А.
Publication of UA89759C2 publication Critical patent/UA89759C2/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Изобретение относится к специфическому связующему элементу, который связывает человеческий домен ED-B фибронектина, где специфический связующий элемент является меченным с помощью изотопаИ и включает мини-иммуноглобулин, слитый с ε-CH4 и димеризованный, который содержит гипервариабельные участки тяжелой и легкой цепи антитела L19. Изобретение также относится к способу получения указанного связующего элемента, композиции, которая его содержит, а также применению данного связующего элемента для производства лекарственного средства для лечения повреждения, связанного с патологическим ангиогенезом, для лечения опухолей и производства диагностического реагента.
UAA200603803A 2003-09-10 2004-09-01 Специфический связующий элемент, радиоактивно меченный 131и, который связывает человеческий ed-в фибронектина UA89759C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03255633A EP1514561A1 (en) 2003-09-10 2003-09-10 Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B

Publications (1)

Publication Number Publication Date
UA89759C2 true UA89759C2 (ru) 2010-03-10

Family

ID=34130349

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200603803A UA89759C2 (ru) 2003-09-10 2004-09-01 Специфический связующий элемент, радиоактивно меченный 131и, который связывает человеческий ed-в фибронектина

Country Status (28)

Country Link
US (2) US20050074401A1 (ru)
EP (3) EP1514561A1 (ru)
JP (1) JP2007505065A (ru)
KR (1) KR101129161B1 (ru)
CN (1) CN100482285C (ru)
AT (1) ATE499949T1 (ru)
AU (2) AU2004269897B2 (ru)
BR (1) BRPI0414272A (ru)
CA (1) CA2536256C (ru)
CR (2) CR8331A (ru)
DE (1) DE602004031635D1 (ru)
DK (1) DK1663320T3 (ru)
EA (1) EA010653B1 (ru)
EC (1) ECSP066499A (ru)
ES (1) ES2361743T3 (ru)
HK (1) HK1092375A1 (ru)
IL (1) IL173560A0 (ru)
ME (1) MEP13108A (ru)
NO (1) NO20061619L (ru)
NZ (1) NZ545640A (ru)
PL (1) PL1663320T3 (ru)
PT (1) PT1663320E (ru)
RS (1) RS20060176A (ru)
SG (1) SG162760A1 (ru)
SI (1) SI1663320T1 (ru)
UA (1) UA89759C2 (ru)
WO (1) WO2005023318A1 (ru)
ZA (1) ZA200602014B (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001242432B2 (en) * 2000-02-24 2007-11-08 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
CN100535013C (zh) * 2002-03-11 2009-09-02 菲洛根股份公司 应用抗体分子对肿瘤血管进行选择性定向
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
EP2085095B1 (en) * 2008-01-17 2012-03-07 Philogen S.p.A. Combination of an anti-EDb fibronectin antibody-IL-2 fusion protein, and a molecule binding to B cells, B cell progenitors and/or their cancerous counterpart
AU2015202204A1 (en) * 2008-04-30 2015-05-14 Immunogen, Inc. Cross-linkers and their uses
KR101764081B1 (ko) * 2008-04-30 2017-08-01 이뮤노젠 아이엔씨 가교제 및 그 용도
WO2011147762A2 (en) * 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
EP3029065B1 (en) * 2013-06-06 2020-05-27 Hefei Lifeon Pharmaceutical Co. Ltd. Human antibody against ed-b domain of fibronectin and uses thereof
GB201621806D0 (en) 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
US10517238B2 (en) 2017-09-18 2019-12-31 Deere & Company Implement optimization by automated adjustments
WO2020249757A1 (en) 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
EP4389146A3 (en) 2020-05-22 2024-10-02 Philogen S.p.A. Tnf-a immunoconjugate therapy for the treatment of brain tumors
CN111808161A (zh) * 2020-06-01 2020-10-23 北京大学 一种对生物化合物进行放射性标记的方法
EP4440599A1 (en) 2022-01-04 2024-10-09 Philogen S.p.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
PT1719528E (pt) 2000-02-24 2012-01-06 Philogen Spa Composições e métodos para tratamento de angiogénese em lesões patológicas
AU2001242432B2 (en) * 2000-02-24 2007-11-08 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
WO2001096599A2 (en) * 2000-06-15 2001-12-20 Philogen S.R.L. Methods for quantitative determination of b-fibronectin in biological fluids and tissues
BR0306715A (pt) * 2002-01-03 2004-12-28 Schering Ag Métodos para diagnóstico e tratamento de tumores
CN100535013C (zh) * 2002-03-11 2009-09-02 菲洛根股份公司 应用抗体分子对肿瘤血管进行选择性定向

Also Published As

Publication number Publication date
AU2010200271A1 (en) 2010-02-18
PT1663320E (pt) 2011-06-07
CN1849144A (zh) 2006-10-18
RS20060176A (en) 2008-08-07
US20090214423A1 (en) 2009-08-27
NO20061619L (no) 2006-04-10
SG162760A1 (en) 2010-07-29
BRPI0414272A (pt) 2006-11-07
ECSP066499A (es) 2006-10-10
SI1663320T1 (sl) 2011-06-30
CR20110168A (es) 2011-06-03
DE602004031635D1 (de) 2011-04-14
AU2004269897A1 (en) 2005-03-17
CA2536256A1 (en) 2005-03-17
CR8331A (es) 2006-10-04
KR20060118430A (ko) 2006-11-23
EP1663320B1 (en) 2011-03-02
EP1514561A1 (en) 2005-03-16
CA2536256C (en) 2013-02-26
EA010653B1 (ru) 2008-10-30
ES2361743T3 (es) 2011-06-21
EA200600494A1 (ru) 2006-08-25
AU2004269897B2 (en) 2009-11-05
PL1663320T3 (pl) 2011-07-29
ATE499949T1 (de) 2011-03-15
KR101129161B1 (ko) 2012-03-28
NZ545640A (en) 2009-05-31
EP2246070A2 (en) 2010-11-03
JP2007505065A (ja) 2007-03-08
EP1663320A1 (en) 2006-06-07
ZA200602014B (en) 2007-05-30
IL173560A0 (en) 2006-07-05
US20050074401A1 (en) 2005-04-07
CN100482285C (zh) 2009-04-29
WO2005023318A1 (en) 2005-03-17
DK1663320T3 (da) 2011-06-06
MEP13108A (en) 2011-05-10
HK1092375A1 (en) 2007-02-09

Similar Documents

Publication Publication Date Title
UA89759C2 (ru) Специфический связующий элемент, радиоактивно меченный 131и, который связывает человеческий ed-в фибронектина
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
SG153825A1 (en) Multivalent immunoglobulin-based bioactive assemblies
IL139452A0 (en) Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of diseases associated with angiogenesis
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
MX2007011064A (es) Anticuerpos contra cd38 para tratamiento de mieloma multiple.
ZA200508389B (en) Humanized antibodies to interferon alpha receptor-1(IFNAR-1)
ATE330967T1 (de) An her2 bindende peptidverbindungen
ATE460946T1 (de) Gebrauch von bispezifischen antikörpern in diagnose und therapie
JP2010523541A5 (ru)
CA2740134C (en) Formulations targeting igfbp7 for diagnosis and therapy of cancer
MXPA04006517A (es) Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores.
WO2009052970A3 (en) Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors
Rasaneh et al. Toxicity of trastuzumab labeled 177Lu on MCF7 and SKBr3 cell lines
YU91403A (sh) Antitela specifična za cd44v6
WO2003105773A3 (en) MUTATIONS OF PDGFRA ACTIVATED AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS
SG148190A1 (en) Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer
WO2004054497A3 (de) Verwendung einer trpm8 aktivierenden substanz zur tumorbehandlung
WO2004022104A3 (en) Foxp2 and uses thereof
EP2674440A3 (en) Multivalent immunoglobulin-based bioactive assemblies
WO2003081250A8 (en) Novel compositions and methods in cancer associated with altered expression of prlr
SI1461360T1 (sl) Konjugati, ki obsegajo protitelo, specifično za domeno ED-B fibronektina, in njihova uporaba za detekcijo in zdravljenje tumorjev
UA109423C2 (uk) Композиція та спосіб для діагностики і лікування пухлини
WO2005023855A3 (en) K203 gene and protein